OncoMed And Lilly To Evaluate Combination Of Demcizumab,Alimta In Lung Cancer

(RTTNews) - OncoMed Pharmaceuticals Inc. (OMED) announced that it has entered into an agreement with Eli Lilly and Co. (LLY). Demcizumab, OncoMed's anti-DLL4 antibody, is being tested in combination with Lilly's Alimta (pemetrexed for injection) and carboplatin for the treatment of first-line advanced non-small cell lung cancer or NSCLC.

As per the terms of this agreement, Lilly will provide clinical supply of Alimta for OncoMed's ongoing Phase 2 DENALI trial.

OncoMed initiated enrollment in the randomized Phase 2 DENALI trial in January 2015 to test the efficacy and safety of demcizumab in combination with Alimta and carboplatin. Alimta is approved as an initial treatment in combination with cisplatin for locally advanced or metastatic NSCLC for patients with non-squamous histology. The DENALI trial is expected to enroll approximately 200 patients with first-line metastatic Stage IV non-squamous NSCLC whose tumors do not have an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation.